Navigation Links
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Date:6/24/2011

>

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideli
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... ... and supplier, announces the launch of their 2nd generation cell therapy POD® design. ... miniPOD CT, but it also represents a new POD® design. , “G-CON ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a global leader ... . To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard ... an example of an accurate label, and pictogram uses and meanings. , “With ...
(Date:7/29/2015)... 29, 2015  Therapath Neuropathology ( www.Therapath.com ), ... with VA and Military Medical centers both domestically ... (ENFD) and Sweat Gland Nerve Fiber Density (SGNFD) ... https://therapath.com/skin ). Demonstration of a ... on punch skin biopsy is a highly sensitive ...
(Date:7/29/2015)... 29, 2015  Indivior PLC (LON: INDV) today announced ... spray was accepted and received Priority Review by the ... of opioid overdose. This naloxone nasal spray comes as ... optimal absorption into the nasal mucosa. 1 The ... individuals may be better equipped to help an opioid ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... Advantage in Key ... Maturity Zone, ST. LOUIS, ... who used DEKALB(R) corn seed stacked,with YieldGard VT Triple(TM) from Monsanto Company ... and,technologies in 2007., Data from nearly 1,700 on-farm field trials showed ...
... Worldwide Rights for All Potential Uses, Excluding U.S. ... for Celiac Disease BASINGSTOKE, England and PHILADELPHIA, ... TSX: SHQ),the global specialty biopharmaceutical company, today announces ... U.S. and Japan, to AT-1001,from Alba Therapeutics Corporation ...
... INDIANAPOLIS, Dec. 14 Eli Lilly and Company,(NYSE: ... join Lilly in,January, 2008, as a Distinguished Lilly Scholar ... absolutely delighted to have Dr. Conley join our team ... Medical Division. "Rob,is a well-known thought leader, clinician and ...
Cached Biology Technology:Farmers Across the U.S. Realize Double-Digit Yield Advantage From DEKALB(R) Corn Seeds With Triple-Stacked Traits 2Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 2Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 3Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar 2
(Date:7/8/2015)... , July 8, 2015 The ... as this summer,s must have products such as wearables, smart ... as popularity for biometrics based devices continues to rapidly grow.  ... Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: GOOG ... FIT ), GoPro, Inc. (NASDAQ: GPRO ) and ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... This release is available in Spanish . , ... for Research in Biomedicine (IRB Barcelona), reveal a surprising new ... to date. Found in the cell membrane, this protein activates ... make the cell divide, grow, migrate, specialise or die. Notch ...
... bacterium found in about 50% of humans worldwide, can cause stomach ... F1000 Medicine Reports , Seiji Shiota and Yoshio Yamaoka discuss ... Infection by the H. pylori bacterium can approach 100% ... many develop problems including stomach ulcers. H. pylori causes ...
... have created a molecular image of a system that moves ... for biology and could provide insights to minimize energy loss ... the country. The research, led by Carrie Wilmot, ... published in the March 12 issue of Science . ...
Cached Biology News:Opposing functions of a key molecule in the development of organisms 2Opposing functions of a key molecule in the development of organisms 3Preventing gastric cancer with antibiotics 2U of Minnesota researcher discovers how electricity moves through cells 2